Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Overview of attention for article published in Therapeutics and Clinical Risk Management, January 2019

Altmetric Badge

Mentioned by

facebook: 1 Facebook page

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 59 Mendeley

Summary Facebook Dimensions citations

So far, Dimensions has found 47 publications that cite this research output.

47

The most recent citing publications are shown below. View all 47 publications that cite this research output on Dimensions.

Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis

Article in Journal of the Egyptian National Cancer Institute (May 2024)

Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study

Article in Clinical Cancer Research (February 2024)

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

Article in Gastroenterología y Hepatología (January 2024)